Table 3.
Knowledge of healthcare professionals on ADR reporting (n = 13).
| Sr.no | Description | Angamo et al. [20] N (%) | Bule et al. [21] N (%) | Nadew et al. [22] N (%) | Adimasu et al. [23] N (%) | Kefale et al. [24] N (%) | Gurmesa et al. [25] N (%) | Kasa et al. Alemu [26] | Goshime et al. [27] N (%) | Denekew et al. [28] N (%) | Gidey et al. [29] N (%) | Kassa et al. [30] N (%) | Hailua et al. [31] N (%) | Shanko et al. [32] N (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ADR is the same as with side effect | 17 (20.73) | 30 (23.1) | NA∗ | 65 (30.4) | 114 (53.5) | NA∗ | 76 (66.67) | 323 (85.2) | 82 (35) | 127 (41.4) | 15 (26.3) | NA∗ | 99 (33.6) |
| 2 | Know the term pharmacovigilance | 16 (19.51) | NA∗ | NA∗ | 46 (21.5) | 66 (31.0) | NA∗ | 23 (20.18) | 176 (46.4) | NA∗ | 90 (29.3) | 21 (36.8) | NA∗ | 87 (29.5) |
| 3 | Know national ADR reporting system | 19 (23.17) | 76 (58.5) | 284 (69.8) | 70 (32.7) | 78 (36.6) | NA∗ | 24 (21.05) | 222 (58.6) | 108 (46.2) | 121 (39.4) | 34 (59.7) | NA∗ | 175 (59.3) |
| 4 | Know the availability of ADR reporting form | 21 (25.61) | 62 (47.7) | 47 (40.2) | NA∗ | 59 (27.7) | 31 (37.4) | 26 (22.81) | 46 (12.1) | 134 (68.8) | NA∗ | 36 (63.2) | NA∗ | 181 (61.36) |
| 5 | ADR are well documented at the time a drug is marketed | 20 (24.39) | 25 (19.2) | NA∗ | NA∗ | 140 (65.7) | NA∗ | NA∗ | 220 (58) | 134 (57.3) | 99 (32.2) | NA∗ | NA∗ | 452 (51.53) |
| 6 | Adequately trained in ADR reporting | NA∗ | 22 (16.9) | 117 (28.7) | NA∗ | NA∗ | NA∗ | NA∗ | NA∗ | NA∗ | NA∗ | NA∗ | NA∗ | NA∗ |
| 7 | Know responsible body | NA∗ | NA∗ | 51 (43.6) | 22 (10.3) | 29 (13.6) | 41 (30.8) | 35 (30.7) | NA∗ | 92 (39.3) | 98 (31.9) | 37 (64.9) | 98 (65.3) | NA∗ |
∗NA: not assessed.